Marshall Wace
GLUE icon

Marshall Wace’s Monte Rosa Therapeutics GLUE Stock Holding History

Marshall Wace’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.6M Buy
1,433,152
+1,034,262
+259% +$19.8M 0.02% 644
2025
Q4 		$6.25M Sell
398,890
-503,944
-56% -$6.79M 0.01% 1059
2025
Q3 		$6.69M Buy
902,834
+456,754
+102% +$2.42M 0.01% 1082
2025
Q2 		$2.01M Buy
446,080
+74,342
+20% +$332K ﹤0.01% 1564
2025
Q1 		$1.72M Sell
371,738
-127,754
-26% -$783K ﹤0.01% 1534
2024
Q4 		$3.47M Buy
499,492
+325,643
+187% +$2.44M ﹤0.01% 1223
2024
Q3 		$921K Buy
+173,849
New +$877K ﹤0.01% 1681

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Marshall Wace's GLUE Position: Q1 2026 in Review

Marshall Wace increased its Monte Rosa Therapeutics (GLUE) stake by 259% in Q1 2026, buying an estimated $19.8M and bringing the position to 1,433,152 shares worth $23.6M. The position accounts for 0.02% of the portfolio, ranked #644.

Marshall Wace first reported a position in GLUE in Q3 2024 and has held it in 7 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Marshall Wace held 1,433,152 shares of Monte Rosa Therapeutics worth $23.6M as of Q1 2026.
  • Marshall Wace bought 1,034,262 Monte Rosa Therapeutics shares in Q1 2026, an estimated $19.8M.
  • Monte Rosa Therapeutics made up 0.02% of Marshall Wace's portfolio in Q1 2026, its #644 holding.
  • Marshall Wace first reported a position in Monte Rosa Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.